Diabetes Australia Ltd and its Controlled Entities

ABN 47 008 528 461

Annual Report - 30 June 2026

Diabetes Australia Ltd and its Controlled Entities
Directors' report
30 June 2026

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Diabetes Australia Ltd (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026.

Directors
The following persons were Directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:

Names	Position	Appointed/Resigned
A Rutherford	President and Board Chair	Appointed 01/09/2023
C Beyers	Board member	Appointed 16/11/2015
G Bunyan	Board member	Appointed 15/06/2021
Z Burgess	Board member	Appointed 20/11/2021
P Flynn	Board member	Appointed 01/11/2025
S Goldsworthy	Board member	Appointed 25/11/2023
A Koumoukelis	Board member	Appointed 21/04/2020
G Ross	Board member	Appointed 04/11/2016
B Fenton	Board member	Resigned 23/01/2026

Information on directors

A Rutherford

Qualifications	B Com, MBA, GAICD, FCPA, SFFin, FGIA
Experience	Board member (from 01/09/2023)
Special Responsibilities	President and Board Chair (appointed 25/11/2023) Member Finance & Investment Committee Member People & Culture Committee

C Beyers

Qualifications	BEng (Environ. Engineering), MBA, GradCert Bus (Philan & Nonprofit), MAAS
Experience	Board member (from 16/11/2015)
Special Responsibilities	Chair Social Impact Committee Member People & Culture Committee

G Bunyan

Qualifications	BA, LLB
Experience	Board member (from 15/06/2021)
Special Responsibilities	Member Risk, Quality & Compliance Committee Member Social Impact Committee

Z Burgess

Qualifications	PhD (Organisational Psychology), MBA, Master Education, FAICD
Experience	Board member (from 20/11/2021)
Special Responsibilities	Chair People & Culture Committee Member Finance & Investment Committee

P Flynn

Qualifications	GAICD, FUniSA, FFICA, SF Fin
Experience	Board member (from 01/11/2025)
Special Responsibilities	Chair Risk, Quality & Compliance Committee (from 27/01/2026) Member Finance & Investment Committee (from 27/01/2026)

S Goldsworthy

Qualifications	BCom, CA, GAICD
Experience	Board member (from 25/11/2023)
Special Responsibilities	Chair Finance Audit & Investment Committee Member Risk, Quality & Compliance Committee

A Koumoukelis

Qualifications	GAICD, LLM, LLB, BCom, Notary, FTIA, Grad Dip (Wills & Estates)
Experience	Board member (from 21/04/2020)
Special Responsibilities	Member Risk, Quality & Compliance Committee Member Social Impact Committee Chair Diabetes Qualified Pty Limited (deregistered 24/06/2026)

G Ross

Qualifications	Endocrinologist, MBBS, FRACP
Experience	Board member (from 4/11/2016)
Special Responsibilities	Member People & Culture Committee (to 27/01/2026) Member Social Impact Committee (from 27/01/2026)

B Fenton

Qualifications	BN, RN, Grad Cert DiabEd
Experience	Board member (from 21/05/2018 to 23/01/2026)
Special Responsibilities	Chair Risk, Quality & Compliance Committee Member Social Impact Committee

Group Chief Executive Officer
Justine Cain
BSc (Psychology), LLB *ANU*. MAICD

Justine Cain has led Diabetes Australia as Group Chief Executive Officer since 2021. Justine has held senior executive and Board roles with listed, privately owned, private equity backed, and not-for-profit organisations in the health, human services, and general insurance sectors. Justine is currently on the Board of UnitingCare Queensland.

Justine's expertise spans transformational leadership roles, strategy development and execution, customer-centric leadership, largescale operational delivery, government relations, advocacy, and complex stakeholder management. Justine is committed to achieving equity in access to health services, population health improvement and judicious use of funding.

Justine holds a Bachelor of Laws and a Bachelor of Science from the Australian National University. Justine has undertaken executive education at both Harvard and INSEAD and is a member of Chief Executive Women and the Australian Institute of Company Directors. In June 2025, Justine's leadership in the health sector was recognised by the Australian Financial Review Women in Leadership Awards with Justine being a finalist in the health services category. In November 2025, Justine was recognised by The CEO Magazine Executive of the Year Awards 2025, receiving a Highly Commended accolade in the Not-for-Profit Executive of the Year category for her leadership of Diabetes Australia.

Company Secretary
Penelope Palmer
GAICD, LLM, B.Ec / LLB, Solicitor New South Wales.

Chief of Corporate Services and a second Company Secretary
Emily Wooden
FCPA, AGIA

Meetings of directors
The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2026, and the number of meetings attended by each director were:

	Directors meetings	
	Eligible to attend	Attended
A Rutherford	5	5
C Beyers	5	5
G Bunyan	5	4
Z Burgess	5	4
P Flynn	3	3
S Goldsworthy	5	5
A Koumoukelis	5	5
G Ross	5	4
B Fenton	3	3

Our vision
To eliminate the impact of diabetes on Australians

Our purpose
To support Australians living with or at risk of diabetes

Our mission
We work with people living with, or at risk of diabetes, their families and carers, health professionals, researchers, funders, other diabetes organisations and the community to positively change people’s lives.

Our ambitious goals
Diabetes Australia will engage with Australians impacted by diabetes, partners and governments to:

- Cure diabetes through groundbreaking research and innovation.
- Drive to eliminate the medical and psychosocial complications caused by diabetes.
- Prevent diabetes
- Reduce the financial burden of diabetes for individuals and the health system.

Principal activities
Diabetes Australia is the national organisation supporting all people living with or at risk of diabetes.

Diabetes Australia works in partnership with people living with or at risk of diabetes, their families and carers, health professionals, researchers, funders, other diabetes organisations and the community to positively change people’s lives.

Diabetes Australia's core focus areas are:
- Being a thought leader, amplifying the voices of the diabetes community and championing the diabetes cause to drive change.
- Advocating and delivering on priorities that have the biggest impact on changing people’s lives and the health system.
- Collaborating locally, nationally and internationally; connecting lived experience with health professionals and research.
- Developing and delivering trusted diabetes services, locally and nationally.
- Leading the agenda, growing funding for and commissioning research.

Diabetes Australia works to bring about change, by providing a national voice and leadership, while maintaining strong local community connections and engagement.

Contributions on winding up
The Company is incorporated under the Corporations Act 2001, registered under the Australian Charities and Not-for-profits Commission Act 2012 and is a Company limited by guarantee.

The Diabetes Australia Constitution was amended on 19 June 2026 to further elevate people affected by diabetes within the company’s purpose and to make a number of governance simplifications and modernisations. The changes were supported by 98% of voters.

On winding up members undertake to contribute up for $50 for persons who became a member prior to 28 January 2021, and $10 for persons who become members after that date.

Operating results
The Diabetes Australia Group consolidated result for the year was an operating deficit of $2,721,710 (2024-2025: deficit of $929,546).

Events after the reporting date
No other matter or circumstance has arisen since 30 June 2026 that has significantly affected or may significantly affect the entity's operations.

Environmental issues
The Company's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or of a state or territory of Australia.

Indemnification and insurance of officers and auditors
The Company indemnifies directors and officers consistent with law.

The Company has paid premiums to insure each of the directors of the Company against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of director of the company, other than conduct involving a wilful breach of duty in relation to the company.

Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 60-40 of the Australian Charities and Not-for-profits Commission Act 2012 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors.

On behalf of the directors

DocuSigned by:
43EE9E1657094BA...

Andrew Rutherford
Director, Chair and President

22 October 2026

Signed by:
79289A8F9DB74E1...

Stephen Goldsworthy
Chair of Finance & Investment Committee

22 October 2026

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Parkline Place
Level 25, 252 Pitt Street
Sydney NSW 2000
Australia

DECLARATION OF INDEPENDENCE BY LEAH RUSSELL TO THE DIRECTORS OF DIABETES AUSTRALIA LIMITED

I declare that, to the best of my knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the audit of Diabetes Australia Limited for the year ended 30 June 2026.

This declaration is in respect of Diabetes Australia Limited and the entities it controlled during the period.

Leah Russell
Director



BDO Audit Pty Ltd

Sydney

22 October 2026

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

Diabetes Australia Ltd and its Controlled Entities
Contents
30 June 2026

Consolidated statement of profit or loss and other comprehensive income	7
Consolidated statement of financial position	8
Consolidated statement of changes in equity	9
Consolidated statement of cash flows	10
Notes to the consolidated financial statements	11
Directors' declaration	25
Independent auditor's report to the members of Diabetes Australia Ltd	26

General information

The financial statements cover Diabetes Australia Ltd as a consolidated entity consisting of Diabetes Australia Ltd and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Diabetes Australia Ltd's functional and presentation currency.

Diabetes Australia Ltd is a not-for-profit unlisted public company limited by guarantee, incorporated and domiciled in Australia. Its registered office and principal place of business is:

19-23 Moore Street
Turner ACT 2612

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 22 October 2026. The directors have the power to amend and reissue the financial statements.

Diabetes Australia Ltd and its Controlled Entities
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Revenue	3	96,084,535	93,398,301
Other income	4	8,955,302	3,719,778
Expenses			
Employee benefits expense	5	(45,657,628)	(38,912,432)
Depreciation and amortisation expense	5	(1,340,988)	(1,286,675)
Agents' remuneration	5	(11,147,042)	(14,880,434)
Research grants	5	(2,380,369)	(1,152,649)
Expenses	5	(47,036,923)	(41,758,820)
Finance costs	5	(198,597)	(56,615)
Deficit before income tax expense		(2,721,710)	(929,546)
Income tax expense		-	-
Deficit after income tax expense for the year attributable to the members of Diabetes Australia Ltd		(2,721,710)	(929,546)
Other comprehensive income			
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year attributable to the members of Diabetes Australia Ltd		(2,721,710)	(929,546)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Diabetes Australia Ltd and its Controlled Entities
Consolidated statement of financial position
As at 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Assets			
Current assets			
Cash and cash equivalents	6	20,868,180	17,876,755
Trade and other receivables	7	4,292,240	3,705,673
Inventories		170,329	94,675
Other financial assets - Term deposits		-	4,102,353
Assets classified as held for sale		-	389,900
Other assets		1,342,259	833,601
Total current assets		26,673,008	27,002,957
Non-current assets			
Other financial assets - Term deposits		642,699	-
Financial assets at fair value through profit or loss	8	39,605,441	33,351,790
Property, plant and equipment	9	17,331,598	20,504,001
Right-of-use assets	10	5,249,595	1,137,696
Total non-current assets		62,829,333	54,993,487
Total assets		89,502,341	81,996,444
Liabilities			
Current liabilities			
Trade and other payables	11	11,159,747	7,279,724
Employee benefits	12	3,571,950	3,204,278
Membership fees received in advance	13	614,999	773,074
Grant and contract liabilities	14	7,929,172	8,254,648
Lease liabilities	15	711,213	603,414
Total current liabilities		23,987,081	20,115,138
Non-current liabilities			
Employee benefits	12	583,384	451,719
Lease liabilities	15	6,921,438	677,439
Total non-current liabilities		7,504,822	1,129,158
Total liabilities		31,491,903	21,244,296
Net assets		58,010,438	60,752,148
Equity			
Issued capital		100	100
Reserves	16	1,287,596	2,092,764
Retained surpluses		56,722,742	58,659,284
Total equity		58,010,438	60,752,148

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Diabetes Australia Ltd and its Controlled Entities
Consolidated statement of changes in equity
For the year ended 30 June 2026

Consolidated	Issued capital	Asset revaluation reserve	Retained surpluses	Total equity
	$	$	$	$
Balance at 1 July 2024	100	3,535,584	59,588,830	63,124,514
Deficit after income tax expense for the year	-	-	(929,546)	(929,546)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(929,546)	(929,546)
Revaluation during the year	-	(1,442,820)	-	(1,442,820)
Balance at 30 June 2025	100	2,092,764	58,659,284	60,752,148

Consolidated	Issued capital	Asset revaluation reserve	Retained surpluses	Total equity
	$	$	$	$
Balance at 1 July 2025	100	2,092,764	58,659,284	60,752,148
Deficit after income tax expense for the year	-	-	(2,721,710)	(2,721,710)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(2,721,710)	(2,721,710)
Transfer on disposal of land and buildings	-	(805,168)	805,168	-
Liquidation of Diabetes Qualified Pty Ltd	-	-	(20,000)	(20,000)
Balance at 30 June 2026	100	1,287,596	56,722,742	58,010,438

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Diabetes Australia Ltd and its Controlled Entities
Consolidated statement of cash flows
For the year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Cash flows from operating activities			
Receipts from grants		79,846,332	80,799,334
Receipts from NDSS-Co payment		5,192,149	5,268,709
Receipts from NDSS registrant contribution		53,690,087	51,080,429
Receipts from NDSS Access point handling fees		7,761,652	7,192,183
Interest received		817,244	1,377,747
Other receipts		11,546,105	10,217,299
Payments to suppliers and employees		(101,892,136)	(94,519,656)
Payment for NDSS registration contribution		(53,469,593)	(50,433,897)
Payment for NDSS Access point handling fees		(7,744,303)	(7,192,183)
GST received/(paid)		(450,695)	(2,155,070)
Interest paid		(198,597)	(56,615)
Net cash from/(used in) operating activities		(4,901,755)	1,578,280
Cash flows from investing activities			
Payments for investments		(1,758,726)	(17,318,145)
Sale of investments		3,549,993	10,452,025
Dividends received		1,325,954	570,199
Payments for property, plant and equipment	9	(106,998)	(299,648)
Proceeds from disposal of Property, Plant and Equipment		5,725,136	-
Net cash (used in)/from investing activities		8,735,359	(6,595,569)
Cash flows from financing activities			
Payment of finance lease liabilities		(842,179)	(273,750)
Net cash used in financing activities		(842,179)	(273,750)
Net increase/(decrease) in cash and cash equivalents		2,991,425	(5,291,039)
Cash and cash equivalents at the beginning of the financial year		17,876,755	23,167,794
Cash and cash equivalents at the end of the financial year	6	20,868,180	17,876,755

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Material accounting policy information

The accounting policies that are material to the consolidated entity are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Basis of preparation
These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards - Simplified Disclosures issued by the Australian Accounting Standards Board ('AASB'), the Australian Charities and Not-for-profits Commission Act 2012 and Charitable Fundraising Act 1991 (NSW) and associated regulations and the Corporations Act 2001, as appropriate for not-for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

Parent entity information
In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 23.

Income tax
As the consolidated entity is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended, it is exempt from paying income tax.

Investments and other financial assets
Deposits are held at amortised costs, over the term of the deposit. Investments in listed shares, managed funds are recognised at fair value, on acquisition and at each reporting period. The gain or loss for realised and unrealised is being recognised through the profit or loss. Transaction costs are recognised directly through the profit or loss.

Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Valuation of land and buildings
Land and buildings are shown at fair value, based on periodic, at least every 3 years, valuations by external independent valuers, less subsequent depreciation and impairment for buildings. The valuations are undertaken more frequently if there is a material change in the fair value relative to the carrying amount. Any accumulated depreciation at the date of revaluation is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset. Increases in the carrying amounts arising on revaluation of land and buildings are credited in other comprehensive income through to the revaluation surplus reserve in equity. Any revaluation decrements are initially taken in other comprehensive income through to the revaluation surplus reserve to the extent of any previous revaluation surplus of the same asset. Thereafter the decrements are taken to profit or loss.

Note 2. Critical accounting judgements, estimates and assumptions (continued)

Estimation of useful lives of assets
The consolidated entity determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Employee benefits provision
As discussed in note 12, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

Note 3. Revenue

	Consolidated	
	2026	**2025**
	$	**$**
Revenue		
Federal government grants - NDSS	45,784,000	46,650,000
State Govt grants - My Health for Life	9,340,392	9,094,989
State Govt grants - Get Healthy Service	5,327,606	5,472,642
State Govt grants - Other	8,233,199	7,960,764
Life for a Child	15,443,224	11,534,534
Other grants	1,235,536	378,341
	85,363,957	81,091,270
Other revenue		
Diabetes Australia member organisation fees	(11,322)	114,182
Interest received	817,244	1,377,747
Commercial partnerships	634,142	1,227,854
Other commercial income	1,317,300	1,052,145
Fundraising	5,729,575	6,167,845
Membership income	1,080,810	1,280,112
Sale of goods	1,152,829	1,087,146
	10,720,578	12,307,031
Revenue	96,084,535	93,398,301

Note 3. Revenue (continued)

Disaggregation of revenue
The disaggregation of revenue from contracts with customers is as follows:

	Consolidated 2026 $	Consolidated 2025 $
Revenue from contracts with customers - AASB 15		
Life for a Child	67,673	270,313
Diabetes Australia member organisation fees	(11,322)	114,182
Interest received	817,244	1,377,747
Other commercial income	1,317,300	1,052,145
Membership income	1,080,810	1,280,112
Sale of goods	1,152,829	1,087,146
	4,424,534	5,181,645
Revenue recognised under AASB1058 Income NFP entities		
Federal government grants - NDSS	45,784,000	46,650,000
State Govt grants - My Health for Life	9,340,392	9,094,989
State Govt grants - Get Healthy Service	5,327,606	5,472,642
State Govt grants - Other	8,233,199	7,960,764
Life for a Child	15,375,551	11,264,221
Other grants	1,235,536	378,341
Commercial partnerships	634,142	1,227,854
Fundraising	5,729,575	6,167,845
	91,660,001	88,216,656
	96,084,535	93,398,301

Accounting policy for revenue and other income recognition
The consolidated entity when assessing revenue and other income applies AASB 1058 Income of Not-for-Profit Entities. AASB 1058 requires the consolidated entity to assess which standard is to apply. The main standards being; AASB 9 Financial instruments, AASB 15 Revenue or AASB 1058 Income of Not-for-Profit Entities.

AASB 1058 Income of Not-for-Profit Entities is recognised on receipt. This is generally applicable for fundraising income.

Revenue from contracts

a) Contracts that contain clauses that meet the definition of AASB 9 Financial Instruments
Contracts that meet the definition of Financial Instruments such as where they contain termination for convenience clauses is recognised as the consolidated entity spends, or has provided the services depending on the terms on the contract.

b) Revenue from contracts with customers – AASB 15 Revenue
Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Note 3. Revenue (continued)

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Revenue from contracts with customers recognition is detailed below:

i) Sale of goods
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

ii) Rendering of services
Revenue from a contract to provide services is recognised over time as the services are rendered based on either a fixed price or an hourly rate.

iii) Grants
Grant revenue is recognised in profit or loss when the consolidated entity satisfies the performance obligations stated within the funding agreements. If conditions are attached to the grant which must be satisfied before the consolidated entity is eligible to retain the contribution, the grant will be recognised in the statement of financial position as a liability until those conditions are satisfied.

iv) Commercial partnerships
Commercial partnerships are recognised when the contract outcome can be reliably measured, control of the right to be compensated for the service has been attained and the stage of completion can be reliably measured.

v) Diabetes Australia Member Organisation/Parent contribution fees
Revenue from Diabetes Australia Member Organisation/Parent Contribution fees are recognised upon the due date in accordance with the Parent's constitution.

vi) Fundraising
Fundraising income is recognised on receipt, unless there are specific performance obligations identified, in which case they are accounted for consistent with Revenue from contracts with customers.

Note 4. Other income

	Consolidated	
	2026	**2025**
	$	**$**
Net foreign exchange gain	-	196,815
Net gain on disposal of property, plant and equipment	705,831	-
Net gain on disposal of investments	779,404	-
Dividend income	1,325,954	677,396
Rental income	801,802	782,246
Unrealised gain on investments	4,063,209	2,022,985
Projected distribution from GIF liquidation	1,266,602	-
Other income	12,500	40,336
Other income	8,955,302	3,719,778

Bequest income
Bequests and donations are recognised on receipts basis.

Note 4. Other income (continued)

Rental income
Rental income arising from operating leases are accounted for on a straight-line basis over the lease terms and is included in revenue in the statement of profit or loss and other comprehensive income.

Dividend income
The consolidated entity recognises dividends and distributions in profit or loss only when the consolidated entity's right to receive payment is established.

Interest income
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Investment gains and losses
The changes in the fair value of investments including any gains or losses on the disposal of investments are recognised in profit and loss.

Volunteer services
The Group has elected not to recognise volunteer services as either revenue or other form of contribution received. As such, any related consumption or capitalisation of such resources received is also not recognised.

Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.

Note 5. Expenses

	Consolidated 2026 $	Consolidated 2025 $
Deficit before income tax includes the following specific expenses:		
Depreciation and amortisation		
Plant and equipment	791,141	875,191
Right-of-use assets	549,847	411,484
	1,340,988	1,286,675
Finance costs		
Interest and finance charges paid/payable on lease liabilities	198,597	56,615
Superannuation expense		
Defined contribution superannuation expense	4,428,119	3,698,404
Employee benefits expense excluding superannuation	41,229,510	35,214,028
Research grants	2,380,369	1,152,649
Agents' remuneration	11,147,042	14,880,434
Other expenses		
Funded program suppliers and contractors	28,341,802	24,613,769
Administrative and general expenses	8,382,748	7,320,971
Publications & promotions	2,216,953	2,935,797
IT support and licenses	7,133,456	6,303,646
Cost of goods sold	614,276	584,637
Net foreign exchange loss	347,688	-
	47,036,923	41,758,820

Defined contribution superannuation expense
Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Finance costs
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

Agents' remuneration-National Diabetes Services Scheme (NDSS)
The National Diabetes Services Scheme (NDSS) is an initiative of the Australian Government administered by Diabetes Australia and delivered to people with diabetes through state and territory diabetes organisations, as NDSS Agents. The scheme is supported by two Health Professional Agents which are the key national organisations dedicated to diabetes in Australia.

The NDSS Agent remuneration is provided to support the delivery of NDSS National Programs and Services. The National Programs and Services are nationally consistent services provided to Registrants that maximise their capacity to manage their diabetes, this includes mechanisms that expand consumer engagement and self-management including access to Registration cards and Starter Packs, telephone support, online support, information and resources, education and other activities such as education of health professionals. The Health Professional Bodies provide a broad range of advice and assistance to assist Diabetes Australia and the Commonwealth deliver the NDSS services

Note 5. Expenses (continued)

Research grants
Research grants are amounts granted in Australia to recipients following a rigorous review process oversighted by the Diabetes Australia Research Advisory panel, specialising in the prevention, management and cure for diabetes. Diabetes Australia has a smaller number of grants that are provided in partnership with like minded organisations. Grants are recognised when paid to the recipient or when there is an obligation to make payment under a contract. Unpaid grants are recognised in the statement of financial position.

Note 6. Cash and cash equivalents

	Consolidated 2026 $	Consolidated 2025 $
Current assets		
Cash in hand	203	203
Cash at bank	19,314,209	14,054,654
Cash at investment fund	1,553,768	3,821,898
	20,868,180	17,876,755

Note 7. Trade and other receivables

	Consolidated 2026 $	Consolidated 2025 $
Current assets		
Trade receivables	972,739	2,536,057
Less: provision for doubtful debt	-	(26,364)
	972,739	2,509,693
Other receivables	1,646,088	1,195,980
Other receivables - GIF Liquidation receivable	1,266,602	-
GST receivable	406,811	-
	3,319,501	1,195,980
	4,292,240	3,705,673

Accounting policy for trade and other receivables
The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Note 8. Financial assets at fair value through profit or loss

	Consolidated 2026 $	Consolidated 2025 $
Non-current assets		
Managed investment portfolio	39,605,441	33,351,790

Accounting policy for financial assets at fair value through profit or loss
Financial assets are classified as financial assets at fair value through profit or loss. Fair value movements are recognised in profit or loss.

Note 9. Property, plant and equipment

	Consolidated 2026 $	Consolidated 2025 $
Non-current assets		
Land and buildings - at fair value	15,000,000	19,710,000
Less: Accumulated depreciation	(269,697)	-
	14,730,303	19,710,000
Fixtures, fittings and furniture - at cost	3,941,945	3,041,293
Less: Accumulated depreciation	(1,621,292)	(2,613,648)
	2,320,653	427,645
Motor vehicles - at cost	-	62,857
Less: Accumulated depreciation	-	(62,857)
	-	-
Computer equipment - at cost	3,754,832	3,745,134
Less: Accumulated depreciation	(3,582,458)	(3,399,979)
	172,374	345,155
Office equipment - at cost	205,639	265,816
Less: Accumulated depreciation	(97,371)	(244,615)
	108,268	21,201
	17,331,598	20,504,001

Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial year are set out below:

Consolidated	**Land and buildings** $	**Fixtures, fittings and furniture** $	**Computer equipment** $	**Office equipment** $	**Total** $
Balance at 1 July 2025	19,710,000	427,645	345,155	21,201	20,504,001
Additions	-	2,213,656	9,698	97,300	2,320,654
Reclassification from Other Current Assets	-	-	-	-	-
Disposal	(4,622,955)	(78,961)	-	-	(4,701,916)
Depreciation expense	(356,742)	(241,687)	(182,479)	(10,233)	(791,141)
Balance at 30 June 2026	14,730,303	2,320,653	172,374	108,268	17,331,598

Accounting policy for property, plant and equipment
Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

Office equipment	2 - 5 years
Computer equipment	2 - 5 years / remaining term of the contract
Fixture, fittings and furniture	3 - 10 years
Buildings	30 years

Note 10. Right-of-use assets

	Consolidated 2026 $	Consolidated 2025 $
Non-current assets		
Right-of-use assets	6,149,418	2,261,562
Less: Accumulated amortisation	(899,823)	(1,123,866)
	5,249,595	1,137,696

Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial year are set out below:

Consolidated	Right-of-use assets $
Balance at 1 July 2025	1,137,696
Additions	4,669,635
Transfers in/(out)	(7,889)
Depreciation expense	(549,847)
Balance at 30 June 2026	5,249,595

Note 11. Trade and other payables

	Consolidated 2026 $	Consolidated 2025 $
Current liabilities		
Trade payables	4,320,481	3,172,799
Accrued Expenses	6,326,144	2,167,057
GST payable	-	148,971
Other payables	513,122	1,790,897
	11,159,747	7,279,724

Accounting policy for trade and other payables
The amounts are unsecured and are usually paid within 30 days of recognition.

Note 12. Employee benefits

	Consolidated 2026 $	Consolidated 2025 $
Current liabilities		
Annual leave	2,588,160	2,309,346
Long service leave	983,790	894,932
	3,571,950	3,204,278
Non-current liabilities		
Long service leave	583,384	451,719

Note 13. Membership fees received in advance

	Consolidated 2026 $	Consolidated 2025 $
Current liabilities		
Membership fees received in advance	614,999	773,074

Note 14. Grant and contract liabilities

	Consolidated 2026	Consolidated 2025
Current liabilities		
State Govt grants - Get Healthy Service	1,705,151	2,879,635
State Govt grants - My Health for Life	1,764,622	888,164
Life for a Child	2,173,498	3,213,341
Other grants	2,217,698	1,126,635
	7,860,969	8,107,775
Other deferred income	68,203	146,873
	7,929,172	8,254,648

Accounting policy for contract liabilities
Contract liabilities represent the consolidated entity's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the consolidated entity recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the consolidated entity has transferred the goods or services to the customer.

If conditions are attached to the grant which must be satisfied before the consolidated entity is eligible to retain the contribution, the grant will be recognised in the statement of financial position as a liability until those conditions are satisfied.

Note 15. Lease liabilities

	Consolidated 2026 $	Consolidated 2025 $
Current liabilities		
Lease liability	711,213	603,414
Non-current liabilities		
Lease liability	6,921,438	677,439
Future lease payments		
Future lease payments are due as follows:		
Within one year	711,213	603,114
One to five years	4,105,534	787,305
More than five years	4,593,058	-
	9,409,805	1,390,419

Note 16. Reserves

	Consolidated 2026 $	Consolidated 2025 $
Revaluation surplus reserve	1,287,596	2,092,764

Revaluation surplus reserve
The reserve is used to recognise increments and decrements in the fair value of land and buildings, excluding investment properties.

Note 17. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by BDO Audit Pty Ltd, the auditor of the company:

	Consolidated 2026 $	Consolidated 2025 $
Audit services - BDO Audit Pty Ltd		
Audit of the financial statements	200,000	197,500

Note 18. Key management personnel disclosures

The following persons had the authority and responsibilities for planning, directing and controlling the activities of the Group, directly or indirectly during the year:

Executive	Position
Justine Cain	Group Chief Executive Officer
Brett Fenton	Chief Health Officer, appointed 1 June 2026
Craig Sedgman	Chief Operating Officer
Emily Wooden	Chief of Corporate Services and CFO
Hayley Gould	Chief People Officer
Laura Fisher	Chief of Staff, appointed 27 October 2025
Nicole McMahon	Chief of Impact and Innovation
Penelope Palmer	Chief of Governance, Legal and Risk
Karen Adamedes	Chief of Staff, resigned 17 December 2025

The expenses recognised for Directors and key management personnel compensation paid during the year:

	Consolidated 2026 $	Consolidated 2025 $
Short - term employee benefits	3,067,328	3,404,589
Post - employment benefits	232,555	276,575
Total compensation	3,299,883	3,681,164

The Board of directors of Diabetes Australia are remunerated out of a pool. The total remuneration paid to all directors of Diabetes Australia as a cohort was within the applicable constitutional limit that applied during the financial year, being $250,000. This encompasses all fees, allowances and benefits provided to directors in their capacity as members of the Board. All remuneration was approved in accordance with governance protocols and disclosed on an aggregate basis as required.

Note 19. Contingent assets

The consolidated entity had no contingent assets as at 30 June 2026 and 30 June 2025.

Note 20. Contingent liabilities

The consolidated entity had no contingent liabilities as at 30 June 2026 and 30 June 2025.

Note 21. Commitments

	Consolidated 2026 $	Consolidated 2025 $
Capital commitments at the reporting date but not recognised as liabilities, payable:		
Within one year	8,400	72,400
One to five years	8,400	16,800
	16,800	89,200
General research grants		
Committed at the reporting date but not recognised as liabilities, payable:		
Within one year	1,061,931	559,766
One to five years	-	111,931
	1,061,931	671,697
Other research grants		
Committed at the reporting date but not recognised as liabilities, payable:		
Within one year	468,233	95,000
One to five years	279,196	40,000
	747,429	135,000

Research grant commitments
As part of the national research program administered through Diabetes Australia Research Trust, two types of grants are awarded. General research grant payments are made on a half yearly basis for one year; Millennium grant payments are made on a half yearly basis for two years.

Note 22. Related party transactions

Parent entity
Diabetes Australia Ltd is the parent entity.

Subsidiaries
Interests in subsidiaries are set out in note 24.

Other related parties
The Members and some subsidiaries of Diabetes Australia Ltd are sub-contracted under the National Diabetes Services Scheme as Agents and two Health Professionals and are paid to provide services to people with diabetes. These payments are included in, described and quantified at note 5.

Note 22. Related party transactions (continued)

Transactions with related parties
Diabetes Australia Limited as parent company, manages and provides administrative support for Diabetes Australia Research Limited which acts as trustee for the Diabetes Australia Research Trust. There were no donations provided by Diabetes Australia or its related entities to the Diabetes Australia Research Trust.

The Glycemic Index Foundation is an Australian not-for-profit health promotion charity whose members are The University of Sydney and Diabetes NSW & ACT (a wholly owned subsidiary of Diabetes Australia). The Glycemic Index Foundation is committed to providing the community with information and the tools required to improve its overall health through scientifically-backed low GI healthy eating principles. Diabetes Australia through Diabetes NSW & ACT did not charge or recover any amount through the Glycemic Index Foundation for administrative support or rent for the year ended 30 June 2026.

Glycemic Index Foundation was placed into liquidation in Feburuary 2025. The liquidation process remained ongoing at 30 June 2026 and had not been completed at the date these financial statements were authorised for issue.

Loans to/from related parties
There were no loans to or from related parties at the current and previous reporting date that have not been eliminated on consolidation.

Note 23. Parent entity information

Statement of profit or loss and other comprehensive income

	Consolidated	
	2026	2025
	$	$
Deficit after income tax	(1,568,622)	(225,694)
Total comprehensive income	(1,568,622)	(225,694)

Statement of financial position

	Consolidated	
	2026	2025
	$	$
Total current assets	23,318,030	19,874,957
Total non-current assets	48,216,538	34,951,330
Total assets	71,534,568	54,826,287
Total current liabilities	57,949,661	46,048,420
Total non-current liabilities	7,504,822	1,129,158
Total liabilities	65,454,483	47,177,578
Equity		
Issued capital	100	100
Retained surplus	6,079,986	7,648,609
Total equity	6,080,086	7,648,709

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2026 and 30 June 2025.

Contingent liabilities
The parent entity had no contingent liabilities as at 30 June 2026 and 30 June 2025.

Capital commitments - Property, plant and equipment
The parent entity had no capital commitments for property, plant and equipment as at 30 June 2026 and 30 June 2025.

Note 23. Parent entity information (continued)

Commitments
The parent entity has agreements with agents where there are commitments for $11,135,630 (2025: $9,578,648).

Material accounting policy information
The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1.

Note 24. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1:

		Ownership interest	
	Principal place of business /	2026	2025
Name	Country of incorporation	%	%
Diabetes Australia Research Limited	Australia	100%	100%
Diabetes Australia Research Trust	Australia	100%	100%
Diabetes NSW&ACT	Australia	100%	100%
Diabetes Australia - Tasmania	Australia	100%	100%
Diabetes Qualified Pty Ltd	Australia	-	100%
Gilicious Management Pty Ltd	Australia	100%	100%
Diabetes Association of Queensland Limited	Australia	100%	100%
Glycemic Index Foundation Australia	Australia	50%	50%
Dormant Entities			
Australian Diabetes Council Pty Ltd	Australia	100%	100%

The consolidated entity held a 100% interest in Diabetes Qualified Pty Ltd. During the year ended 30 June 2026, Diabetes Qualified Pty Ltd was deregistered effective 24 June 2026 and removed from the Group. The entity was dormant and held net assets of $20,000 immediately prior to deregistration.

Note 25. Events after the reporting period

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Diabetes Australia Ltd and its Controlled Entities
Directors' declaration
30 June 2026

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Australian Accounting Standards - Simplified Disclosures, the Australian Charities and Not-for-profits Commission Act 2012, the Charitable Fundraising Act 1991 (NSW) and associated regulations, the Corporations Regulations 2001 and other mandatory professional reporting requirements;

- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2026 and of its performance for the financial year ended on that date; and

- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and

- internal controls are appropriate and effective in accounting for income received and applied from any fundraising appeal.

Signed in accordance with a resolution of directors made pursuant to section 60.15(2) of the *Australian Charities and Not-for-profit Commission Regulation 2022.*

On behalf of the directors

DocuSigned by:
43EE9E1657094BA...

Andrew Rutherford
Director, Chair and President

22 October 2026

Signed by:
79289A8F9DB74E1...

Stephen Goldsworthy
Chair of Finance & Investment Committee

22 October 2026

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Parkline Place
Level 25, 252 Pitt Street
Sydney NSW 2000
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of Diabetes Australia Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Diabetes Australia Limited (the registered entity) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including material accounting policy information, and the responsible entities' declaration.

In our opinion the accompanying financial report of Diabetes Australia Limited, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

(i) Giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and

(ii) Complying with Australian Accounting Standards – Simplified Disclosures and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The directors are responsible for the other information. The other information comprises the information contained in the directors' report and annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon, which we obtained prior to the

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

date of this auditor's report, and the annual report, which is expected to be made available to us after that date.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to the directors and will request that it is corrected. If it is not corrected, we will seek to have the matter appropriately brought to the attention of users for whom our report is prepared.

Responsibilities of responsible entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Simplified Disclosures and the ACNC Act, and for such internal control as the responsible entities determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, responsible entities are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The responsible entities of the registered entity are responsible for overseeing the Group's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at:

https://www.auasb.gov.au/media/apzlwn0y/ar3_2024.pdf

This description forms part of our auditor's report.

BDO Audit Pty Ltd

BDO

Leah Russell

Director

Sydney, 23 October 2026